ArticleArchives of Razi Institute2025
Antibacterial, Antifungal, Antibiofilm, and Cytotoxicity Activity of Astragalus Baba-Alliar Extract Against Main Causes of Dental Root Canal Infections.
Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of endodontic treatment is paramount: to completely eradicate bacterial infection within the dental pulp and root canal system. This study aimed to evaluate the Antimicrobial, antibiofilm, and cytotoxicity activity of Astragalus baba-alliar (A. baba-alliar) extract against the main causes of dental root canal infections, which areEnterococcus faecalis and Candida albicans. After preparing the methanolic extract from A. baba-alliar, phytochemical analysis was conducted to determine the content of secondary metabolites, followed by the determination of minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and minimum fungicidal concentration (MFC), against Candida albicans (C. albicans) and Enterococcus faecalis (E. faecalis).Subsequently, the ability of the methanolic extract to inhibit biofilm formation was investigated using the microtiter plate method. The cytotoxic effects of the methanolic extract on normal human gingival fibroblast cells (HGF-1) and oral cancer cells (KB) were evaluated using the MTT reduction method. Based on the phytochemical results, the presence of flavonoids, terpenoids, saponins, and polysaccharides in this plant extract was confirmed. The total phenol and flavonoid content were determined to be 4.23 mg GEA/g DW and 2.61 mg QE/g DW, respectively. The methanol extract of the plant, both alone and in combination with nystatin, exhibited a significant anti-candidal effect against C. albicans, while alone and especially in combination with chlorhexidine, it demonstrated a significant antibacterial effect against E. faecalis. Moreover, the extract alone and in combination with nystatin, induced biofilm formation in C. albicans with an MBIC50 of 4.6 μg/ml, 64 μg/ml, and 0.25 μg/ml, respectively. Similarly, the extract alone and combined with chlorhexidine inhibited biofilm formation in E. faecalis with a minimum biofilm inhibitory concentration (MBIC50) of 42.6 μg/ml and 1.16 μg/ml, respectively. The calculated Selectivity Index (SI) exceeding 2 (SI=2.72) indicates the extract's selective cytotoxicity toward cancer cells while maintaining negligible toxicity toward normal cells. Based on the antimicrobial properties uncovered in this research, the study is anticipated to lay the groundwork for clinical trials and subsequent investigations into the plant's active compounds. Such endeavors hold potential for application across various industrial sectors, including food, pharmaceuticals, and medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.